| pubmed-article:12749896 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12749896 | lifeskim:mentions | umls-concept:C0038477 | lld:lifeskim |
| pubmed-article:12749896 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:12749896 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:12749896 | pubmed:dateCreated | 2003-5-16 | lld:pubmed |
| pubmed-article:12749896 | pubmed:abstractText | High affinity binding for mu and kappa opioid receptors has been observed in analogues of cyclazocine, ethylketocyclazocine and naltrexone where the prototypic (of opiates) phenolic OH group was replaced with a formamide (-NHCHO) group. For the 8-formamide analogue of cyclazocine, binding is highly enantiospecific (eudismic ratios approximately 2000 for mu and kappa) with K(i) values </=1 nM observed for the (2R,6R,11R)-isomer, (-)-4. A preliminary SAR revealed that affinity is very sensitive to substitution on the formamide appendage. | lld:pubmed |
| pubmed-article:12749896 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12749896 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12749896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12749896 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12749896 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:12749896 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:12749896 | pubmed:author | pubmed-author:BidlackJean... | lld:pubmed |
| pubmed-article:12749896 | pubmed:author | pubmed-author:LouRongliangR | lld:pubmed |
| pubmed-article:12749896 | pubmed:author | pubmed-author:YeYingchunY | lld:pubmed |
| pubmed-article:12749896 | pubmed:author | pubmed-author:WentlandMark... | lld:pubmed |
| pubmed-article:12749896 | pubmed:author | pubmed-author:SunXufengX | lld:pubmed |
| pubmed-article:12749896 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12749896 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:12749896 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:12749896 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12749896 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12749896 | pubmed:pagination | 1911-4 | lld:pubmed |
| pubmed-article:12749896 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:meshHeading | pubmed-meshheading:12749896... | lld:pubmed |
| pubmed-article:12749896 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12749896 | pubmed:articleTitle | Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues. | lld:pubmed |
| pubmed-article:12749896 | pubmed:affiliation | Department of Chemistry, Rensselaer Polytechnic Institute, Troy, NY 12180, USA. wentmp@rpi.edu | lld:pubmed |
| pubmed-article:12749896 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12749896 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:12749896 | lld:chembl |
